Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty

Circulation

Volumn 96, Issue 1, 1997, Pages 166-173

  Horie, Hajime ^a   Takahashi, Masayuki ^a   Izumi, Masafumi ^a   Takaoka, Atsushi ^a   Fujita, Tamotsu ^b   Sakamoto, Taizo ^b   Kito, Osamu ^b   Okamura, Hiroshi ^b   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Okamura Memorial Hospital   (Japan)

Author keywords

Angiography lipids; Cholesterol; Lipoproteins; Stenosis

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY OBSTRUCTION; CORRELATION FUNCTION; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; TRIGLYCERIDES;

EID: 0030744582     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Holms DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM, Van Raden MJ, Mock MB. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53:77c-81c.
2. Nobuyoshi M, Kimura T, Nosaka H. Restenosis after successful coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12:616-623.
3. Wolinsky H. Insights into coronary angioplasty-induced restenosis from examination of atherogenesis. Am J Cardiol. 1987;60:65B-67B.
4. Essed CE, Van Den Brand M, Becker AE. Transluminal coronary angioplasty and early restenosis: fibrocellular occlusion after wall laceration. Br Heart J. 1983;49:393-396.
5. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;6:369-375.
6. Waller BF, Gorfinkel HJ, Roger FJ, Kent KM, Roberts WC. Early and late morphologic changes in major epicardial coronary arteries after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1984;53:42C-47C.
7. Waller BF, McManus BM, Gorfinkel HJ, Kishel JC, Schmidt ECH, Kent KM, Roberts WC. Status of major epicardial coronary arteries 80 to 150 days after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1983;51:81-84.
8. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawbar TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707-714.
10. Austin GE. Lipids and vascular restenosis. Circulation. 1992;85:1613-1615.
11. Foley JB, Younger K, Foley D, Kinsella A, Molloy M, Crean PA, Greaty G, Gibney M, Walsh MJ. Lipids and fatty acids and their relationship and restenosis. Cathet Cardiovasc Diagn. 1992;25:25-60.
12. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Isolation and characterization of the two major apoproteins in human lipoprotein(a). J Biol Chem. 1983;258:4582-4589.
13. Utermann G, Weber W. Protein composition of LP(a) lipoprotein for human plasma. FEBS Lett. 1983;154:357-361.
14. Fless GM, Rolik CA, Scanu AM. Heterogeneity of human plasma lipoprotein(a): isolation and characterization of lipoprotein subspecies and their apoproteins. J Biol Chem. 1984;259:11470-11478.
15. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrin and fibrinogen. Proc Natl Acad Sci U S A. 1989;86:3847-3851.
16. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-303.
17. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
18. Rosengren A, Wilhemsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case control study in a general population sample of middle aged men. Br Med J. 1990;301:1248-1251.
19. Hoefler G, Harnoncourt F, Paschke E, Mirth W, Pfeiffer KH, Kostner GM. Lipoprotein Lp(a): a risk factor for myocardial infarction. Atherosclerosis. 1988;8:398-401.
20. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
21. Dahlen GH, Guyton JR, Atter M, Farmer JA, Gotto AM. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
22. Hearn HA, Demasio SJ Jr, Roubin GS, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol. 1990;66:1176-1180.
23. Hoff HF, Beck GJ, Skibinski CI, Jurgens G, O'Neill J, Kramer J, Lytle B. Serum Lp(a) levels as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;77:1238-1244.
24. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Atherosclerosis. 1989;9:579-592.
25. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, De Bakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Atherosclerosis. 1989;9:593-603.
26. Johansson SR, Wiklund O, Karlsson T, Hjalmarson A, Emanuelsson H. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. Eur Heart J. 1991;12:1020-1028.
27. Tenda K, Saikawa T, Maeda T, Sato Y, Niwa H, Inoue T, Yonemochi H. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J. 1993;57:789-795.
28. Haase J, Di Mario C, Slager CJ, van der Giessen WJ, den Boer A, de Feyter PJ, Reiber JHC, Verdouw PD, Serruys PW. In-vivo validation of on-line and off-line geometric coronary measurements using insertion of stenosis phantoms in porcine coronary arteries. Cathet Cardiovasc Diagn. 1992;27:16-27.
29. Reiber JHC, Serruys PW, Koojman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiers JCH, den Boer A, Hugenholtz PG. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation. 1985;71:280-288.
30. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary artery stenosis. Am J Cardiol. 1974;33:87-94.
31. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis: Manual of Laboratory Operations. Washington, DC: Government Printing Office; 1982. US Dept of Health, Education, and Welfare publication NIH 75-628.
32. 2 precipitation technique in human serum. Clin Chim Acta. 1986;158:33-41.
33. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18: 499-508.
34. Brandstorm A, Johnson D, Dahlen G, Rånby M. LP(a) levels in a healthy population measured by new enzyme linked immunosorbent assay. Thromb Haemost. 1989;62:573. Letter.
35. Ellis SG, Roubin GS, King SB III, Douglas JS Jr, Cox WR. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. Am J Cardiol. 1989;63:30-34.
36. Macdonald RG, Henderson MA, Hirshfeld JW Jr. Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty: a report from the M-HEART Group. Am J Cardiol. 1990;66:926-931.
37. Hirshfeld JW Jr, Schwartz JS, Jugo R, Macdonald RG, Goldberg S, Savage MP, Bass TA, Vetrovec G, Cowley M, Taussig AS, Whitworth HB, Margolis JR, Hill JA, Pepine CJ, for the M-HEART Investigators. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol. 1991;18:647-656.
38. Bourassa MG, Lespérance J, Eastwood C, Schwartz L, Côté G, Kazim F, Hudon G. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1991;18:368-376.
39. Shah PK, Amin J. Low high-density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation. 1992;85:1279-1285.
40. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995;92:31-38.
41. Schumacher M, Eber B, Tiran A, Toplak H, Luha O, Gasser R, Klein W. Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angioplasty. Cardiology. 1992;80:345-348.
42. Albers JJ, Marcovina SM, Lodge MS. The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem. 1990;36:2019-2026.
43. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
44. Hegele RA, Freeman MR, Langer A, Connelly PW, Armstrong PW. Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. Circulation. 1992;85:2034-2038.
45. Block P, Myler R, Stertzer S, Fallon J. Morphology after transluminal angioplasty in human beings. N Engl J Med. 1981;305:382-385.
46. Kochi T, Takebayashi S, Block PC, Hiroki T, Nohuyoshi M. Arterial changes after coronary angioplasty: results at autopsy. J Am Coll Cardiol. 1987;10:592-599.
47. Soward AL, Essed CE, Serruys PW. Coronary arterial findings after accidental death immediately after successful coronary angioplasty. Am J Cardiol. 1985;56:794-795.
48. Mizuno K, Kurita A, Imazeki N. Pathological findings after coronary angioplasty. Br Heart J. 1984;52:588-590.
49. Hearn JA, Donokue BC, Ba'albaki BA, Douglas JS, King SB, Lembo NJ, Roubin GS, Sgoutas DS. Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous trunsluminal coronary angioplasty. Am J Cardiol. 1992;69:736-739.
50. Cooke T, Sheaham R, Foley D, Reilly M, D'Arcy O, Jauch W, Gibney M, Gearty G, Crean P, Walsh M. Lipoprotein(a) in restenosis after percutaneous coronary angioplasty and coronary artery disease. Circulation. 1994;89:1593-1598.
51. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Circulation. 1991;84:160-167.
52. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
53. Violaris AG, Melkert R, Herrman JPR, Serruys PW. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty. Circulation. 1996;93:889-897.
54. Laurence AH. Role of platelets and thrombosis in mechanism of acute occlusion and restenosis after angioplasty. Am J Cardiol. 1987;60:20B-28B.
55. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
56. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Atherosclerosis. 1990;10: 240-245.
57. Dahlen G, Ericson C, Berg K. In vitro studies on the interaction of isolated LP(a) lipoprotein and other serum lipoproteins with glycosaminoglycans. Clin Genet. 1978;14:36-42.